Haloperidol for the Treatment of Delirium in ICU Patients.
Nina Christine Andersen-RanbergLone M PoulsenAnders PernerJørn WetterslevStine EstrupJohanna HästbackaMatt MorganGuiseppe CiterioJesus CaballeroTheis LangeMaj-Brit N KjærBjørn H EbdrupJanus EngstrømMarkus H OlsenMarie Oxenbøll ColletCamilla B MortensenSven-Olaf WeberA Sofie AndreasenMorten H BestleBülent UsluHelle Scharling PedersenLouise Gramstrup NielsenHans C Toft BoesenJacob V JensenLars NebrichKirstine La CourJens LaigaardCecilie HaurumMarie W OlesenChristian Overgaard-SteensenBo WestergaardBjørn A BrandGitte Kingo VesterlundPernille Thornberg KyhnauvVibe S MikkelsenSimon Hyttel-SørensenInge de HaasSøren R AagaardLine O NielsenAnne S EriksenBodil Steen RasmussenHelene BrixThomas HildebrandtMartin Schønemann-LundHans Fjeldsøe-NielsenAnna-Maria KuivalainenOle Mathiesennull nullPublished in: The New England journal of medicine (2022)
Among patients in the ICU with delirium, treatment with haloperidol did not lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo. (Funded by Innovation Fund Denmark and others; AID-ICU ClinicalTrials.gov number, NCT03392376; EudraCT number, 2017-003829-15.).